Business Context and Reporting Period
Company: Catheter Precision, Inc. (VTAK)
Filing Type: Form 8-K (Current Report)
Date: April 16, 2025
Event: Potential acquisition of assets related to a late-stage treatment for acute decompensated heart failure via a newly formed subsidiary, Cardionomix, Inc.
Key Financial Metrics and Transaction Terms
This filing does not report standard financial performance metrics (revenue, profit, cash flow) for a specific period. Instead, it outlines the proposed financial structure of a potential asset acquisition:
- Consideration: Issuance of 1,000,000 restricted shares of Company common stock and a $1.5 million promissory note.
- Note Terms: 4% simple interest per annum; no principal or interest payable until maturity (3 years from issuance).
- Subsidiary Ownership: Company holds 82%; CEO David Jenkins holds 5%; FatBoy Capital L.P. holds 7%; other associates hold 6%.
- Liquidity Status: The Company states it does not have sufficient liquidity to fund its business for the next three to six months without additional financing or strategic transactions.
Material Changes and Operational Status
New Subsidiary Formation: In February 2025, the Company formed Cardionomix, Inc. to pursue the acquisition of assets from Cardionomic, Inc., a Delaware corporation that has ceased operations.
Asset Details: The target assets include patents and trademarks for the Cardiac Pulmonary Nerve Simulation (CNPS) System. The acquisition is proposed on an "AS IS" and "WHERE IS" basis with limited representations from the seller.
Internal Controls: The Company disclosed that its internal controls and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.
Outlook, Risks, and Contingencies
Timeline: The Company hopes to sign and close the transaction in the first half of the second quarter of 2025, though no agreement is currently signed.
Financing Needs: Post-acquisition, Cardionomix will require substantial funds to develop the assets. The Company is discussing financing with potential investors, which may involve issuing additional securities and diluting the Company's ownership interest.
Key Risks:
- Transaction Failure: Negotiations may fail, or the seller may abandon the deal for a better offer.
- Stock Price Volatility: A drop in the Company's stock price could deter the seller from finalizing the stock-based consideration.
- Regulatory Hurdles: FDA review is expected to be costly and lengthy with no guarantee of approval.
- Technical Challenges: Pilot studies indicated issues with nerve fatigue, unstable hemodynamics, and the need for device modifications.
- Liquidity Crisis: Immediate need for capital to sustain operations independent of the acquisition.
Investor Verification Checklist
- Verify the current status of negotiations with Cardionomic (assignment for the benefit of creditors), LLC.
- Confirm the Company's current cash balance and runway given the disclosed liquidity constraints.
- Review the specific terms of the proposed promissory note and any covenants attached to the stock issuance.
- Assess the progress of remediation efforts regarding the material weaknesses in internal controls identified in 2024.
- Monitor for updates on the subsidiary's ability to secure third-party financing for asset development.